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Abstract
Study Design—In vitro experiment using human intervertebral disc (IVD) cells and adenovirus-
therapeutic gene constructs.
Objectives—To examine the biologic effect of “cocktail” therapeutic gene transfer to human
IVD cells in three dimensional cultures.
Summary of Background Data—. Gene therapy is regarded as a potential option for the
treatment of degenerative disc disease. Although various anabolic genes have previously been
introduced for this purpose, cocktail gene transfer of anabolic genes to IVD cells has never been
attempted.
Materials and Methods—Human IVDs were harvested during surgical disc procedures and
cultured. We prepared recombinant adenovirus constructs bearing the TGF-β1 gene (Ad/TGF-β1),
the IGF-1 gene (Ad/IGF-1), and the BMP-2 gene (Ad/BMP-2). Transgene expression was
detected by luciferase assays, enzyme linked immuno-sorbent assays, and Western blot analysis.
Newly synthesized proteoglycan was measured by 35S-sulfate incorporation on Sephadex G-25M
in PD 10 columns. Human IVD cells were transduced by single, double, and triple combination of
Ad/TGF-β1, Ad/IGF-1, Ad/BMP-2 with an MOI of 75, then cultured three-dimensionally in
alginate beads.
Results—Transgene expression was detected at 18 hours after viral transduction. IVD cultures
with Ad/TGF-β1, Ad/IGF-1, Ad/BMP-2 (MOI of 75) showed 2.9, 1.8, and 1.9 fold increases,
respectively, in proteoglycan synthesis compared to control. Human IVD cultures with double
gene combination (MOI of 75) showed 3.2 to 3.9 fold increases of proteoglycan synthesis. Lastly,
Human IVD cultures with triple gene combination (TGF-β1+IGF-1+BMP-2 genes with an MOI of
75) transfer demonstrated 4.7 fold increase in proteoglycan synthesis compared control.
Conclusion—Combination or “cocktail” gene therapy offers a promising mechanism for
maximizing matrix synthesis with low dose of adenoviral mixtures, circumventing systemic, local
toxic effect, and immune response.
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Introduction
Intervertebral disc (IVD) disease accounts for approximately one quarter of all cases of back
pain and is a leading source of health care cost, lost wages and patient morbidity. 1 The IVD
has two structural components, the nucleus pulposus and the annulus fibrosus. Proteoglycan,
a major component of the nucleus pulposus, is known to imbibe water and provide positive
swelling pressure for the nucleus pulposus. 2 The IVD provides biomechanical stability that
stems from the high positive pressure in the nucleus pulposus combined with the integrity of
the tensile annulus fibrosus. 3 Therefore having an appropriate amount of proteoglycan in
the nucleus pulposus, together with an intact annulus, is believed to be crucial for the
optimal function of the IVD. Although the etiology and pathophysiology of IVD
degeneration are largely unknown, some evidence indicates that it results from an imbalance
in proteoglycan synthesis and catabolism, apoptosis, and other imbalances in complex self-
regulatory mechanisms involving various cytokines and enzymes. 2, 4–9 The loss of
proteoglycan may directly affect the biomechanical functions of IVD, altering loading of the
facet joint and other structures, causing degenerative changes of the spine. 10
Growth factors such as transforming growth factor-β1 (TGF-β1), insulin like growth
factor-1 (IGF-1), osteogenic protein-1 (OP-1), and bone morphogenetic protein-2 (BMP-2)
appear to have promising therapeutic properties such as stimulating proteoglycan synthesis
and maintaining the chondrogenic phenotype of IVD. 11–14 Nevertheless direct and
repetitive injections of growth factor protein(s) to the IVD do not appear feasible for chronic
types of disease, such as disc degeneration, that require sustained delivery of growth
factor(s) throughout the disease course. An alternative means of delivering exogenous
growth factors is the genetic modification of IVD cells through gene transfer such that the
cells continuously manufacture the desired growth factors endogenously.
The definition of gene therapy has become quite broad. It no longer refers strictly to the
treatment of an existing disorder by replacement of a defective gene with a functional copy
by gene transfer. 15 Instead, gene therapy is now defined by use of nucleic acid transfer,
either RNA or DNA, to treat or prevent a disease.16 In previous studies, we successfully
used an adenovirus-mediated gene transfer technique to directly deliver exogenous genes to
rabbit lumbar IVDs in vitro and in vivo.17, 18 Furthermore we demonstrated the
susceptibility of human IVD cells to adenovirus-mediated gene transfer.19 Despite the
promising effects of gene therapy, the therapeutic transfer of single genes using high doses
of viral vector appears hazardous in terms of systemic effects, cytotoxicity, and immune
response.21 Combination or cocktail therapy appears to have distinct advantages that
enhance therapeutic potential and lessen side effects. To achieve maximal anabolic effect in
terms of proteoglycan synthesis, selection of therapeutic genes for cocktail therapy is of
prime importance. In literature survey, growth factors i.e., TGF-β1, IGF-1, and BMP-2
appear to be feasible candidates for matrix regeneration of IVD. Hence, therapeutic genes of
TGF-β1, IGF-1, and BMP-2 are selected for the experiment. 11, 12, 14 Viral induced toxicity
is thought to be critical in the clinical application of gene therapy, especially in adenovirus
mediated gene delivery. 21–24 Therapeutic cocktail gene transfer might represent an
important tool to enhance the regeneration of the matrix of the IVD while reducing the
administered viral dose.
Accordingly, the objectives of this in vitro experimental study were first, to attempt cocktail
gene therapy with human IVD cells cultured in three dimensional alginate beads and second,
to determine which cocktail or combinations can produce synergistic or additive effect on
matrix synthesis.
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Materials and Methods
All of the experimental protocols were approved by the human subjects Institutional Review
Board.
Patient data and tissue acquisition procedures
Lumbar IVD tissue was obtained from twenty-two patients (Age range 25 to 59 years)
during surgical disc procedures performed for herniated disc and spinal stenosis.
Classification of the intervertebral disc of each patient was performed based on magnetic
resonance images of each disc as described in the literature.24 IVDs with grade III and IV
degeneration were exclusively harvested to minimized the effect of IVD degeneration on
transgene expression and proteoglycan synthesis. An attempt was made by the operating
surgeon (JDK, SHM) to carefully obtain tissue from the central aspect of the disc to
optimize harvest of only the nucleus pulposus and the inner annulus fibrosus.
The disc tissue specimens were transported in sterile GBSS to the laboratory, less than 20
minutes following surgical removal and then were washed with Gey’s balanced salt solution
(GBSS, GIBCO-BRL, Grand Island, NY) to remove blood and bodily fluid contaminants.
Adenoviral vectors
Four different adenoviral constructs were prepared for this study: Adenovirus luciferase
construct (Ad/luciferase) encoding firefly luciferase as a viral control, adenovirus TGF-β1
construct (Ad/TGF-β1), adenovirus IGF-1 construct (Ad/IGF-1), and adenovirus BMP-2
construct (Ad/BMP-2). Each recombinant adenoviral vector originated from replication-
deficient type 5 adenovirus lacking the E1 and E3 regions of the genome.15 Each luciferase,
TGF- β1, IGF-1, BMP-2 genes were cloned respectively into the E1 region under the control
of the human cytomegalovirus early promoter. Recombinant virus was grown in transformed
human embryonic kidney 293 cells and underwent CsC1 density gradient purification. Titers
were determined by optical density at 260nm (OD260) and a standard plaque assay. 25, 26
Disc cell culture method
Any obvious granulation tissue, dense outer annulus, and cartilaginous endplate tissues were
removed carefully from the disc tissue specimens. Disc cells were then isolated from the
inner annulus and nucleus pulposus as described previously.27 Briefly, the dissected
specimens were minced with a scalpel into fragments approximately two cubic millimeters
in volume. Disc tissues from the nucleus pulposus and inner annulus were digested for 60
minutes at 37° C under gentle agitation in a medium composed of equal parts of Ham’s F-12
medium and Dulbecco’s Modified Eagle Medium (F12/DMEM, GIBCO-BRL, Grand
Island, NY) containing 5% heat-inactivated fetal bovine serum (FBS, GIBCO-BRL, Grand
Island, NY) with 0.2% pronase (Calbiochem, La Jolla, CA) and 0.004% deoxyribonuclease
II type IV (DNAse, Sigma, St. Louis, MO). The tissue to solution ratio was 1:5. The tissue
was then washed 3 times with F12/DMEM and digested overnight under the same
conditions, except that the pronase was replaced with bacterial 0.02% collagenase type II
(Sigma, St. Louis, MO). The cells were washed once with F12/DMEM, pelleted by
centrifugation at 2000 RPM for 10 minutes, and then resuspended in F12/DMEM.
Suspended cells were filtered through a sterile nylon mesh filter (pore size: 75 um) to
remove large cell aggregates and debris, and then were counted in a haemocytometer and
plated in 24-well plates (Falcon, Franklin Lakes, NJ) at a density of approximately 5×105
cells/ml. Primary cultures were sustained for 3 weeks in F12/DMEM containing 10% FBS,
1% v/v penicillin, streptomycin and nystatin (all antibiotics from GIBCO-BRL, Grand
Island, NY) in a 5% CO2 incubator with humidity. Culture medium was changed twice a
week.
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Cell viability was determined by trypan blue exclusion test. 28 Under microscopic
observation, round birefringent cells without blue staining were regarded as viable cells, and
the percentage of viable cells to total cells was calculated.
Incorporation of isolated cells into alginate beads
The preparation of intervertebral disc cells in alginate beads was performed as described
elsewhere.28 Briefly, isolated cells from primary culture with trysinization were resuspended
in sterile 0.15M NaCl containing 1.2% low-viscosity alginate (Kelco, Chicago, IL) at a
density of one million cells per milliliter, then slowly expressed through a 22 gauge needle
in a dropwise fashion into 102mM CaCl2 solutions. After instaneous gelation, the beads
were allowed to polymerize further for a period of 10 minutes in the CaCl2 solution. The
beads were then washed once in 10 volume of 0.15M NaCl and three times in 10 volumes of
F12/DMEM medium. The beads were finally placed in complete culture medium. Ten beads
(containing an average number of cells/bead) were cultured in each well of a 24-well plate.
Depolymerization of alginate bead
To remove cells from the alginate bead, wells were rinsed twice with 0.15M NaCl with
gentle pipetting into the well. The rinse solution was incubated for 1 minute and was
aspirated off. Three times the volume of alginate in dissolving buffer (55mM sodium citrate
and 0.15M NaCl) was added to the wells and plates were incubated at 37 °C for 10 minutes
with shaking.
In-vitro transduction of the human disc cells
At full confluence, the disc cell cultures were organized into four groups. In Group 1 (Saline
or viral control): treatment of IVD cells in monolayer culture with normal saline or Ad/
luciferase and incorporation of treated cells into alginate beads. In Group 2 (Single
therapeutic gene transfer): adenoviral transduction with Ad/TGF-β1, Ad/IGF-1, and Ad/
BMP-2 respectively in monolayer culture and incorporation of transduced cells into alginate
beads, In Group 3 (Double therapeutic gene transfer): adenoviral transduction with double
combination of Ad/TGF-β1, Ad/IGF-1, and Ad/BMP-2, i.e., Ad/TGF-β1+Ad/IGF-1, Ad/
TGF-β1+Ad/BMP-2, and Ad/IGF-1+Ad/BMP-2. In Group 4 (Triple therapeutic gene
transfer): adenoviral transduction with triple combination of Ad/TGF-β1, Ad/IGF-1, and
Ad/BMP-2. Viral concentration was calculated as 100 adenoviral particles for 1 plaque-
forming unit (PFU) and 1 PFU per IVD cell as 1 multiplicity of infection (MOI). PFU of
5×105 in each culture well rendered 1 MOI of adenoviral transduction since approximately
5×105 IVD cells were cultured in 24 well culture plates. Total viral concentration was
adjusted to 75 MOI in viral control, single, double, and triple combination groups. For
example, concentration of each adenoviral construct in double combination group was 37.5
MOI and concentration of each adenovirus construct in triple combination group was 25
MOI, therefore the total concentration of adenoviral vector was 75 MOI.
In detail, conditioned culture medium was aspirated and cultures were rinsed three times
with GBSS. Then cultures were treated with 50 ul of GBSS containing Ad/luciferase, Ad/
TGF-β1, Ad/IGF-1, Ad/BMP-2 in single or combination as described previously. Then
cultures were incubated in 5% CO2 at 37° C with humidity for one hour under gentle
agitation to facilitate transduction. Afterwards IVD cells were incorporated into alginate
beads as described above.
After each transduction procedure, Newman Tytell serumless media (Gibco BRL, Grand
Island, NY) was added to cultures to detect transgene expression. Conditioned culture
medium was added to each well, and the alginate beads were further incubated in 5% CO2 at
37° C with humidity for 1 week with daily medium change.
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Analysis of transgene expressions
Luciferase assay—Luciferase gene expression was assessed using a standard luciferase
assay.29 The culture medium was removed and the alginate beads were rinsed twice with
PBS. Then beads were depolymerized as described. Cell culture lysis buffer (25 mM Tris-
phosphate, pH 7.8, 2 mM dithiothreitol, 2 mM diaminocyclohexane-tetraacetic acid, 10%
glycerol, and 1% Triton X-100) was added in each well to cover the cells. After brief
incubation, cells were scraped from the culture well and transferred to a microcentrifuge
tube (Fisher Scientific, Pittsburgh, PA). After brief centrifugation (12,000g for 5 seconds),
the supernatant (cell extract) was transferred to a new tube. Luciferase assay reagent (20
mM Tricine, pH 7.8, 1.07mM (MgCO3)4Mg(OH)2 5H2O, 2.67 mM MgSO4, 0.1 mM
EDTA, 33.3 mM dithiothreitol, 270 uM coenzyme A, 470 uM D-luciferin, and 530 uM
ATP) was mixed with the cell extract. Light production over a period of 30 seconds was
measured with luminometer (Autolumat LB 953, EG & G, Gaithersburgh, MI) and
expressed as relative light units (RLU).
Enzyme linked immunosorbent assay for TGF-β1 transgene expression—TGF-
β1 content was measured by enzyme linked immunosorbent assay (ELISA) (ELISA kit for
human TGF -β1; R&D System, Inc., Minneapolis, MN). Because this receptor based ELISA
detects only levels of bioactive TGF-β1, serial time course samples of supernatant from IVD
cell culture after transduction with Ad/TGF-β1 (150 MOI) were collected and subjected to
acidification to preactivate them, thus enabling quantification of the total (active +latent)
protein by ELISA.
Western Blot analysis for TGF-β1, IGF-1, and BMP-2 transgene expressions—
Transduced human IVD cells were sonicated in 200 ul ice cold lysis buffer (1x PBS, 70mM
β-GP, 0.1 mM sodium vanadate, 2 mM MgCl2, 1 mM EGTA, 1 mM DTT, 0.5% triton
X-100, 0.2 mM PMSF, 1/1000 v/v protease inhibitor) for 5 sec. Crude lysates were
centrifuged at 15,000 rpm for 15 min at 4°C to remove cellular debris. Supernatant was
transferred to another tube. Protein concentration was determined by Bradford assay
(BioRad) using bovine serum albumin as the standard. Proteins were separated by Tricine-
SDS-PAGE gel electrophoresis. Proteins were diluted in 5x gel loading buffer, boiled for 5
min, and loaded onto 13% resolving gel containing a 4% stacking gel. After electrophoresis,
proteins were transferred to Hybond-P (Amersham pharmacia) membrane. Western analysis
was performed by incubating the membranes with the indicated primary antibody followed
by horseradish peroxidase-conjugated secondary antibody according to the rapid detection
protocol provided by Amersham Pharmacia. Immune complexes on the membranes were
visualized by enhanced chemiluminescence using an ECL kit. Primary antibody was used at
a 1:2000-anti-α-tublin, 1:2000- anti-TGF- β1(rabbit IgG, Santa Cruz), 1:500-anti-IGF-1, or
1:2000-anti-BMP-2(mouse IgG, R&D) dilution.
Measurement of newly synthesized proteoglycan
On day 2, cultures were administered with fresh Newman-Tytell serumless medium
containing 35S-sulfate (final concentration 20 °Ci/ml). After a period of 4 hours, alginate
cultures were depolymerized as described previously and depolymerized cultures with
labeling medium were extracted at 4° C for 48 hour by addition of an equal volume of 8M
guanidine hydrochloride, 20 mM EDTA and a mixture of proteinase inhibitors.30 For
quantitative evaluation of 35S-sulfate labeled proteoglycans, aliquots (200 uL) of the stored
extracts were eluted on Sephadex G-25M in PD 10 columns (Pharmacia Biotech, Uppsala,
Sweden) under dissociative conditions.30 Then 1 mL of fractions were collected in
scintillation vials, mixed with 6 mL of scintillation mixture (Ultima Gold, Packard, Meriden,
CT), and counted in a liquid scintillation counter (Packard #1900 TR, Mariden, CT).
Scintillation count was normalized by cell number of each experimental group.
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Statistical analysis
Data are presented as mean ± the standard deviation. SPSS software was utilized for data
analysis (SPSS Inc, Chicago, IL). One-way analysis of variance with Fisher’s protected LSD
post-hoc test and Student t-test was conducted to examine difference of proteoglycan
synthesis among the experimental groups. Significance level was set at p<0.05.
Results
Disc cell yield and viability
The average yield of cells from the disc tissue was 5×106 cells/gram of harvested tissue
Initial cell viability upon isolation was 95% to 100% based on the trypan blue exclusion
tests. The transduction and incorporation into alginate beads were found to be innocuous for
cell survival, with the cells retaining 90–95% viability immediately after the procedure.
Luciferase gene expression
IVD cells with Ad/luciferase with an MOI of 75, cultured in alginate beads, exhibited a
marked increase in luciferase activity (8.8 ±0.6) × 107 RLU over saline control (Figure 1).
The result of this marker gene study proves highly efficient transduction in monolayer and
expression of transduced gene even in alginate beads.
Time course of TGF-β1 transgene expression
The supernatant from IVD cells with Ad/TGF-β1, cultured in monolayer, exhibited
increased production of total TGF-β1 content at 18, 24, 48, 72 hours after viral transduction
(p<0.05) (Figure 2)
TGF-β1, IGF-1, and BMP-2 transgene expression
Western analysis demonstrated that IVD cell cultures transduced with Ad/TGF-β1, Ad/
BMP-2, Ad/IGF-1 all expressed their respective proteins, while cultures with saline and Ad/
luciferase (mock virus) showed no detectable protein expression (Figure 3).
Proteoglycan synthesis
There was no statistically significant increase in newly synthesized proteoglycan in the Ad/
luciferase group compared to saline control. In IVD culture, transduced with a single gene,
there was a statistically significant 2.9 fold increase of newly synthesized proteoglycan in
the Ad/TGF-β1 group, a 1.8 fold increase in the Ad/IGF-1 group, and a 1.9 fold in the Ad/
BMP-2 group compared to the saline and viral controls (p<0.05). In cultures transduced with
a double combination of therapeutic genes, there was a 3.9 fold increase of newly
synthesized proteoglycan in the Ad/TGF-β1+Ad/IGF-1 group, a 3.2 fold increase in Ad/
IGF-1+Ad/BMP-2, and a 3.5 fold increase in Ad/TGF-β1+Ad/BMP-2 compared to the
saline and viral controls (p<0.05). In culture transduced with a triple combination of
therapeutic genes, there was a 4.7 fold increase of newly synthesized proteoglycan in the
Ad/TGF-β1+Ad/IGF-1+Ad/BMP-2 group compared to saline and viral controls (p<0.05)
(Figure 4).
Discussion
Gene therapy involves the introduction of a nucleic acid sequence encoding a gene of
interest into a population of cells such that the cells express that particular gene.15 By
altering the genetic complement of a cell, the cell can serve as a “protein producing factory”
affecting not only its own metabolism, but the metabolism of adjacent non-genetically
altered cells.31 To advocate gene therapy as a treatment for disc degeneration, several steps
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are needed: first, in vitro and in vivo feasibility of marker gene transfer to confirm
susceptibility of disc tissue to gene transfer, second, elucidation of biologic effects of the
therapeutic gene in disc tissue, and finally therapeutic gene therapy in an appropriate animal
model for disc degeneration. In previous studies, we demonstrated the feasibility of marker
gene transfer and the biologic modulatory effect of a therapeutic gene (TGF-β1) in rabbits,
and we also demonstrated that human IVD cells are genetically modifiable in vitro by
adenovirus-mediated gene transfer.17–19 The feasibility of human in vivo studies is virtually
limited because of ethical reasons. Therefore thorough validation of the biologic modulatory
effect of gene therapy in an acceptable in vitro system is mandatory before planned clinical
trials.
Efficient and reliable methods to deliver exogenous gene(s) to the intervertebral disc have
become available with recent developments in molecular biology and vector technology.
The optimal combination of exogenous genes for the management of degenerative disc
disease, however, is unknown. While the cDNAs of anabolic growth factors as well as
catabolic cytokines and enzymes are available, most research efforts to date have focused on
enhancing the anabolic aspects of disc metabolism—hence the emphasis has been on
anabolic growth factors. The current study has investigated the effect of combination or
“cocktail” gene therapy on disc matrix synthesis by human IVD cells cultured in three-
dimensional alginate beads. The current study has demonstrated robust anabolic effects on
matrix synthesis which seem to be additive, depending upon the combination of genes
applied. Enhanced biologic effects with cocktail gene therapy provide a valuable mechanism
to reduce the amount of viral vector in gene therapy. For instance, IVD cells with Ad/TGF-
β1 with an MOI of 75 showed a 2.9 fold increases in proteoglycan synthesis, while triple
gene cocktail (Ad/TGF-β1, Ad/IGF-1, Ad/BMP-2) with the same MOI demonstrated a 4.7
fold increase in proteoglycan synthesis compared to control cultures. To achieve 2.9 fold
incrseases of proteoglycan synthesis, approximately 45 MOI of adenoviral vector would be
sufficient with triple gene combination, while 75 MOI of adenoviral vector is needed with
Ad/TGF-β1. Gene therapy with lower doses of virus has several advantages, firstly,
avoiding systemic local toxic effects, secondly, circumventing immune response and
minimizing the possible occurrence of replicating virus. 32, 33
The mechanism underlying the enhanced biologic effect of cocktail gene therapy using
TGF-β1, IGF-1, and BMP-2 gene is still under investigation. Possible explanations are
receptor saturation, negative feedback, and different intracellular signal transduction
pathways. TGF-β1 and BMP-2 both function in the TGF-superfamily pathway, nevertheless,
after receptor activation, Smad2 and Smad4 for TGF- β1, Smad1 and Smad4 for BMP-2
were activated and form complex with Smad4.34 Furthermore IGF-1 utilizes a different
signal transduction pathway than the TGF-superfamily pathway.35 Therefore different signal
molecules and pathways of TGF-β1, IGF-1, and BMP-2 enable enhanced biologic responses
such as the proteoglycan synthesis induced by cocktail gene therapy.
Extrapolation of the current in vitro results obtained with cultured human disc cells to in
vivo clinical situations is, of course, premature and requires further validation of the
combination gene therapy approach in animal models. We are also actively characterizing
gene expression profiles as a function of the disc degeneration process to better guide the
optimal selection of genes for therapeutic/prophylactic intradiscal gene therapy approaches.
In conclusion, combination or “cocktail” gene therapy offers a promising mechanism for
maximizing matrix regeneration with a minimal dose of adenoviral mixtures.
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Figure 1.
Transgene expression of luciferase gene in human disc cells with Ad/luciferase with an MOI
of 75, cultured in alginate beads. Cultures with Ad/luciferase exhibited marked increase in
luciferase expression compared to control culture with saline.
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Figure 2.
Transgene expression of human intervertebral disc cells with Ad/TGF-β1, cultured in
monolayer, and measured at 18, 24, 48, 72 hours after adenoviral transduction.
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Figure 3.
Western blot analysis for transgene expression for TGF-β1, IGF-1, BMP-2 gene. Alpha-
tubulin was utilized as control. Mock denotes Ad/luciferase served as viral control. Anti-
TGF- β1, anti-IGF-1, anti-BMP-2A antibody were utilized in the assay.
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Figure 4.
Proteoglycan synthesis as measured 35S-sulfate incorporation after transduction of single,
double and triple combination of Ad/TGF-β1, Ad/IGF-1, and Ad/BMP-2. Total amount of
adenovirus were 75 MOI in all groups. * p<0.05
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